Ansa Biotechnologies
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology, Synthetic biology |
| Founded 📆 | 2018 |
| Founders 👔 | Dan Lin-Arlow, Sebastian Palluk |
| Headquarters 🏙️ | , Emeryville, California , United States |
Area served 🗺️ | |
Key people | Jason T. Gammack (CEO) Dan Lin-Arlow (CSO) Sebastian Palluk (CTO) |
| Members | |
Number of employees | |
| 🌐 Website | ansabio |
| 📇 Address | |
| 📞 telephone | |
Ansa Biotechnologies is an American biotechnology company based in Emeryville, California. The company develops enzymatic DNA synthesis methods designed to generate long and complex synthetic DNA sequences. *Nature* described Ansa’s approach as a significant new method in DNA manufacturing,[1] and both *GEN* and *The Scientist* have discussed the company’s technology in the context of broader advances in synthetic biology.[2][3]
Background
Ansa Biotechnologies was founded in 2018 by Dan Lin-Arlow and Sebastian Palluk following research at the University of California, Berkeley.[3] In 2024, *GenomeWeb* reported the appointment of Jason T. Gammack as chief executive officer, with Lin-Arlow becoming chief scientific officer.[4]
Research and Technology
Ansa’s work centers on enzymatic DNA synthesis using terminal deoxynucleotidyl transferase (TdT) conjugated with nucleotide triphosphates, an alternative to phosphoramidite chemistry.[1] *The Scientist* reported that the platform achieved a 99.9% stepwise yield for a 1,005-base construct and enabled parallel synthesis of hundreds of oligonucleotides.[3] A study published in *Frontiers in Bioengineering and Biotechnology* documented the de novo synthesis of a 1,005-base oligonucleotide using the system.[5] A 2023 review article also cited Ansa’s approach as part of efforts to close the “gene writing gap” in synthetic biology.[6]
Applications
Coverage in *GEN* noted that Ansa began offering early access to long synthetic DNA constructs up to 50 kilobases in 2025.[2] Independent reporting has discussed the potential applications of such constructs in genomics and synthetic biology research.[1]
Collaborations
In 2020, Ansa partnered with TeselaGen to explore DNA design and automation workflows.[7]
References
- ↑ 1.0 1.1 1.2 Seydel, Caroline (July 22, 2025). "Made-to-order DNA goes big: new tech doubles size of custom genetic sequences". Nature. 643 (8073): 1146–1147. Bibcode:2025Natur.643.1146S. doi:10.1038/d41586-025-02261-y. PMID 40696021 Check
|pmid=value (help). - ↑ 2.0 2.1 "Ansa Biotechnologies rolls out early access program for long, complex synthetic DNA orders". GEN. February 10, 2025.
- ↑ 3.0 3.1 3.2 "Enzymatic DNA synthesis: Going to great lengths". The Scientist. June 13, 2024.
- ↑ "People News: Ansa Biotechnologies' Jason Gammack, Dan Lin-Arlow". GenomeWeb. March 18, 2024.
- ↑ "Enzymatic DNA synthesis: demonstration of a 1,005-base oligonucleotide". Frontiers in Bioengineering and Biotechnology. August 22, 2023. doi:10.3389/fbioe.2023.1208784. PMID 37476479 Check
|pmid=value (help). - ↑ Hoose, A.; Vellacott, R.; Storch, M.; Freemont, P. S.; Ryadnov, M. G. (January 10, 2023). "DNA synthesis technologies to close the gene writing gap". PMC. 7 (3): 144–161. doi:10.1038/s41570-022-00456-9. PMC 9869848 Check
|pmc=value (help). PMID 36714378 Check|pmid=value (help). - ↑ "TeselaGen partners with Ansa Biotechnologies on DNA automation". TeselaGen. June 15, 2020.
This article "Ansa Biotechnologies" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Ansa Biotechnologies. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
